Askina Hydrocolloid and Askina Hydrocolloid/Thin react with a wound exudate to form a soft get which permits dressing removal with minimal damage to newly formed tissue. It may be used for superficial wounds e.g. minor abrasions. It may also be used for the following indications under the supervision of a healthcare professional:

•Dermal Ulcers, including

Partial & Full Thickness Wounds
· Pressure Ulcers, Stages I-IV
· Arterial and Venous Leg Ulcers
•Burns Second Degree
•Donor Sites
As an Aid in the Prevention of Skin Breakdown

Device Description

In accordance with section 510(k) for the Federal Food, Drug, and Cosmetic Act, B. Braun Medical, Inc. intends to introduce into interstate commerce Askina Hydrocolloid Thin. They are multi layered dressings consisting of an absorbent hydrocolloid layer. This layer reacts with a wound exudate to form a soft gel which permits the dressing to be removed with minimal damage to newly formed tissue. Askina Hydrocolloid provides a moist wound environment while absorbing excess fluid. The moist environment is supportive to healing and promotes autolytic debridement of necrotic fissue.

AI/ML Overview

The provided document is a 510(k) premarket notification for a medical device (Askina Hydrocolloid/Thin dressings) and does not describe acceptance criteria, a study proving device performance against acceptance criteria, or any of the detailed information requested regarding AI/algorithm performance.

Instead, the document focuses on:

Substantial Equivalence: Establishing that the Askina Hydrocolloid/Thin dressings are substantially equivalent to a legally marketed predicate device (Duoderm CGF). This is the primary regulatory hurdle for 510(k) submissions, not the demonstration of specific performance metrics against pre-defined acceptance criteria through a study as would be detailed for a novel device or AI algorithm.
Device Description: General information about the dressing's composition and function.
Materials Testing: Stating that materials conform to ISO Standard 10993, which relates to biocompatibility, not specific performance outcomes.
Safety and Effectiveness: A general statement about finished product testing for release specifications (physical testing, visual examination) but without providing quantifiable acceptance criteria or study results.
Indications for Use: The FDA's approved uses for the device and specific limitations on labeling claims.

Therefore, I cannot extract the requested information from the provided text. The document does not contain details about:

Acceptance criteria and reported device performance: No specific performance metrics (e.g., healing rates, infection reduction) or quantitative acceptance criteria are presented. The "acceptance criteria" mentioned are internal quality control procedures which ensure the product conforms to design specifications, not clinical performance metrics.
Sample size, data provenance, number of experts, adjudication method for a test set: No clinical or algorithmic test set is described.
MRMC comparative effectiveness study: Not mentioned.
Standalone (algorithm-only) performance: Not applicable as this is a physical medical device, not an AI algorithm.
Type of ground truth: Not applicable.
Sample size and ground truth establishment for a training set: Not applicable.

Summary

{0}------------------------------------------------

JAN 28 1999

II 510{k} Summary of Safety and Effectiveness in Accordance with SMDA'90

August 31, 1997

B. Braun Medical, Inc 824 Twelfth Avenue Bethlehem, PA 18018 (610)691-5400

Mark S. Alsberge, Regulatory Affairs Director Contact:

Askina Hydrocolloid Product Name:
Trade Name: Dressing

Classification name:

General and Plastic Surgery Class I, 80FRO 21 CFR 878.4060

SUBSTANTIAL EQUIVALENCE TO:

510(k) number	Name	Applicant
K881050	Duoderm CGF	Convatec, Division of E.R.Squibb & Sons, Inc.

Device Description:

P. 7

K973227

1 The term "substantially equivalent" as use herein is intended to be a determination of substantial equivalence from an FDA -regulatory point of view under the Federal Food, Drug, and Cosmetic Act and relates to the fact that the product can be marketed without premarket approval or reclassification. These products may be considered distinct from a patent point of view. The term "substantially equivalent" is not applicable to and does not diminish any patent claims related to this product or the technology used to manufacture the product.

{1}------------------------------------------------

Material:

Askina Hydrocolloid and Askina Hydrocolloid Thin are composed of materials that have been tested in accordance with the ISO Standard 10993 and have been determined to be suitable for the intended use of this product.

Substantial equivalence:

Askina Hydrocolloid and Askina Hydrocolloid Thin are similar in materials, form and intended use to the Duoderm CGF cleared by Convatec. Division of E.R. Squibb & Sons Inc. There are no new issues of safety or effectiveness raised by Askina Hydrocolloid and Askina Hydrocolloid Thin.

Safety And Effectiveness:

All finished products are tested and must meet all required release specifications before distribution. The array of testing required for release include, but are not limited to; physical testing, visual examination (in process and finished product).

The physical testing is defined by Quality Control Test Procedure documents. These tests are established testing procedures and parameters which conform to the product design specifications.

The testing instruction records for each of the individually required procedures are approved, released, distributed and revised in accordance with document control cGMP"s.

{2}------------------------------------------------

DEPARTMENT OF HEALTH & HUMAN SERVICES

Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular border with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is a stylized symbol featuring three abstract human profiles facing to the right, with flowing lines above and below them, resembling a bird in flight or flowing water.

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

JAN 28 1999

Mr. Mark Alsberge B. Braun Medical, Inc. 901 Marcon Boulevard Allentown, Pennsylvania 18103-9341

Re: K973227 Re: Trade Name: Askina Hydrocolloid Thin Regulatory Class: Unclassifed Product Code: KMF Dated: November 2, 1998 Received: November 3, 1998

Dear Mr. Alsberge:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act). You may, therefore, market your device subject to the general controls provisions of the Federal Food, Drug, and Cosmetic Act (Act) and the following limitations:

This device may not be labeled for use on third degree burns. 1.
This device may not be labeled as having any accelerating effect on the rate of 2. wound healing or epithelization.
This device may not be labeled as a long-term, permanent, or no-change dressing, or 3. as an artificial (synthetic) skin.
This device may not be labeled as a treatment or a cure for any type of wound. 4.

The labeling claims listed above would be considered a major modification in the intended use of the device and would require a premarket notification submission (21 CFR 807.81).

The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practices, labeling, and prohibitions against misbranding and adulteration.

{3}------------------------------------------------

Page 2 - Mr. Mark Alsberge

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval) it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations (CFR), Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Good Manufacturing Practices (GMP) for Medical Devices: General GMP regulation (21 CFR Part 820) and that, through periodic GMP inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4595. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or 301-443-6597 or at its internet address http://www.fda.gov/cdrh/dsmamain.html.

Sincerely yours,

Celia M. Witten, Ph.D., M.D. Director Division of General and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{4}------------------------------------------------

510(k) Number (if known): K973227

Device Name: Askina Hydrocolloid/Thin

Indications For Use:

•Dermal Ulcers, including

Partial & Full Thickness Wounds
· Pressure Ulcers, Stages I-IV
· Arterial and Venous Leg Ulcers
•Burns Second Degree
•Donor Sites
As an Aid in the Prevention of Skin Breakdown

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

(Division Sign-Off)
Division of General Restorative Devices
510(k) Number K973227

Prescription Use (Per 21 CFR 801.109) OR

Over-The-Counter Use

(Optional Format 1-2-9G)

Regulation Number and Section

§ 880.5090 Liquid bandage.

(a)
Identification. A liquid bandage is a sterile device that is a liquid, semiliquid, or powder and liquid combination used to cover an opening in the skin or as a dressing for burns. The device is also used as a topical skin protectant.(b)
Classification. Class I (general controls). When used only as a skin protectant, the device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 880.9.